Detailed explanation of the mechanism of action and target characteristics of afatinib (Gitari)

Afatinib (Afatinib) is a second-generation irreversible tyrosine kinase inhibitor (TKI), mainly used to treat patients with epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Its mechanism of action and target characteristics can be analyzed in detail from the following aspects:

First of all, afatinib can selectively target EGFR and its homologous family members, including HER2 (EGFR span>ErbB2) and HER4 (ErbB4). It irreversibly inactivates the receptor tyrosine kinase by covalently binding to the ATP binding site, thus blocking the continued activation of downstream signaling pathways. This irreversible inhibitory effect allows afatinib to have significant efficacy in patients with EGFR-sensitive mutations (such as Exon19 deletions and L858R mutations) while reducing the risk of drug resistance.

Secondly, the target characteristics of afatinib determine that it has a comprehensive inhibitory effect on tumor cell proliferation, survival and migration. By blocking the EGFR-mediated RAS-RAF-MEK-ERK and PI3K-AKT-mTOR signaling pathways, afatinib not only inhibits the proliferation of tumor cells, but also induces apoptosis, inhibits angiogenesis and tumor metastasis. This multiple mechanism enables it to show a relatively durable therapeutic effect in EGFR mutation-positive advanced NSCLC.

Third, the irreversible effect of afatinib is more advantageous than that of first-generation EGFR inhibitors (such as erlotinib and gefitinib). The first-generation drugs mainly reversibly bind ATP sites and are prone to produce drug-resistant mutations (such as T790M), while afatinib can cover more The EGFR mutation subtypes, including partial resistance mutations, delay the emergence of resistance, thereby improving the progression-free survival of patients (PFS).

Finally, in clinical application, the target characteristics of afatinib also mean that its side effects are related to the widespread expression of EGFR. Adverse reactions such as rash, diarrhea, and stomatitis are mostly related to the inhibition of EGFR receptors on normal cells. Therefore, during clinical use, it is necessary to optimize safety through dose adjustment and symptomatic treatment, while ensuring its anti-tumor effect.

In summary, afatinib achieves comprehensive blockade of signaling pathways by irreversibly inhibiting EGFR and its cognate receptors, thereby exerting anti-tumor effects. Its target characteristics make it effective in patients with EGFR mutations and NSCLC. At the same time, attention needs to be paid to the management of related adverse reactions.

Reference materials:https://www.drugs.com/